Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$13.58 - $17.36 $99,025 - $126,589
7,292 Added 14.67%
56,991 $896,000
Q4 2023

Feb 14, 2024

SELL
$10.11 - $16.54 $86,096 - $140,854
-8,516 Reduced 14.63%
49,699 $801,000
Q3 2023

Nov 14, 2023

BUY
$12.46 - $15.48 $6,155 - $7,647
494 Added 0.86%
58,215 $740,000
Q2 2023

Aug 14, 2023

BUY
$13.28 - $15.96 $766,534 - $921,227
57,721 New
57,721 $812,000
Q4 2020

Feb 03, 2021

SELL
$51.77 - $66.18 $3.72 Million - $4.76 Million
-71,891 Closed
0 $0
Q3 2020

Nov 04, 2020

SELL
$43.8 - $58.16 $188,602 - $250,436
-4,306 Reduced 5.65%
71,891 $3.69 Million
Q2 2020

Aug 05, 2020

SELL
$37.05 - $65.03 $824,584 - $1.45 Million
-22,256 Reduced 22.61%
76,197 $4.55 Million
Q1 2020

May 06, 2020

SELL
$33.63 - $69.4 $146,895 - $303,139
-4,368 Reduced 4.25%
98,453 $4.05 Million
Q4 2019

Feb 07, 2020

BUY
$31.7 - $69.93 $158,880 - $350,489
5,012 Added 5.12%
102,821 $6.4 Million
Q3 2019

Nov 04, 2019

BUY
$19.95 - $38.85 $356,785 - $694,793
17,884 Added 22.38%
97,809 $3.32 Million
Q2 2019

Aug 07, 2019

BUY
$21.05 - $26.21 $1.68 Million - $2.09 Million
79,925 New
79,925 $1.8 Million

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.